Perspective Therapeutics’ (CATX) “Buy” Rating Reaffirmed at BTIG Research

Perspective Therapeutics (NYSEAMERICAN:CATX)‘s stock had its “buy” rating reiterated by analysts at BTIG Research in a research note issued on Tuesday,Benzinga reports. They presently have a $14.00 price target on the stock. BTIG Research’s target price would suggest a potential upside of 168.20% from the stock’s previous close.

CATX has been the subject of a number of other research reports. Piper Sandler began coverage on shares of Perspective Therapeutics in a report on Thursday, February 19th. They issued an “overweight” rating and a $16.00 price target for the company. HC Wainwright boosted their target price on Perspective Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. UBS Group reiterated a “buy” rating and issued a $7.00 price target (down from $18.00) on shares of Perspective Therapeutics in a report on Friday, November 21st. B. Riley Financial lowered their price objective on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Finally, Wedbush restated an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $12.38.

Perspective Therapeutics Trading Up 4.4%

Perspective Therapeutics stock opened at $5.22 on Tuesday. The business’s fifty day moving average is $4.22 and its two-hundred day moving average is $3.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.66 and a quick ratio of 8.66. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its earnings results on Monday, March 16th. The company reported ($0.51) earnings per share for the quarter. The business had revenue of $0.04 million during the quarter. Perspective Therapeutics had a negative net margin of 9,841.86% and a negative return on equity of 40.03%. On average, equities analysts forecast that Perspective Therapeutics will post -0.88 EPS for the current year.

Institutional Trading of Perspective Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. boosted its stake in Perspective Therapeutics by 184.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after acquiring an additional 5,475 shares during the last quarter. Aigen Investment Management LP bought a new position in shares of Perspective Therapeutics during the fourth quarter worth $28,000. nVerses Capital LLC acquired a new position in shares of Perspective Therapeutics in the 4th quarter valued at $31,000. Engineers Gate Manager LP bought a new stake in shares of Perspective Therapeutics in the 4th quarter valued at $35,000. Finally, AXQ Capital LP raised its stake in Perspective Therapeutics by 24.2% during the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock worth $35,000 after buying an additional 2,481 shares during the period. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.